Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection

References

• Anderson, K. B., Guest, J. L., & Rimland, D. (2004). Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy Era: Data from the HIV Atlanta VA cohort study. Clinical Infectious Diseases, 39(10), 1507–1513. https://doi.org/10.1086/425360
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration. (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. The Lancet, 372(9635), 293–299. https://doi.org/10.1016/S0140-6736(08)61113-7
   PubMed Web of Science ®Google Scholar
• Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A. (2018). Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology, 68(3), 827–838. https://doi.org/10.1002/hep.29811
   PubMed Web of Science ®Google Scholar
• Backus, L. I., Belperio, P. S., Shahoumian, T. A., & Mole, L. A. (2019). Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology, 69(2), 487–497. https://doi.org/10.1002/hep.29408
   PubMed Web of Science ®Google Scholar
• Baden, R., Rockstroh, J. K., & Buti, M. (2014). Natural history and management of hepatitis C: Does sex play a role? Journal of Infectious Diseases, 209(suppl 3), S81–S85. https://doi.org/10.1093/infdis/jiu057
   PubMed Web of Science ®Google Scholar
• Berenguer, J., Rodríguez, E., Miralles, P., Von Wichmann, M. A., Lopez-Aldeguer, J., Mallolas, J., Galindo, M. J., Van Den Eynde, E., Tellez, M. J., Quereda, C., Jou, A., Sanz, J., Barros, C., Santos, I., Pulido, F., Guardiola, J. M., Ortega, E., Rubio, R., Jusdado, J. J.,  … , Gonzalez-Garcia, J. (2012). Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clinical Infectious Diseases, 55(5), 728–736. https://doi.org/10.1093/cid/cis500
   PubMed Web of Science ®Google Scholar
• Bhattacharya, D., Belperio, P. S., Shahoumian, T. A., Loomis, T. P., Goetz, M. B., Mole, L. A., & Backus, L. I. (2017). Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clinical Infectious Diseases, 64(12), 1711–1720. https://doi.org/10.1093/cid/cix111
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2019). National vital statistics reports. Deaths: Final Data for 2017, 68 (9). https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf
   Google Scholar
• Centers for Disease Control and Prevention. (2020). Viral hepatitis surveillance — United States, 2018. https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. Published July 2020
   Google Scholar
• Chen, Y. C., Thio, C. L., Cox, A. L., Ruhs, S., Kamangar, F., & Wiberg, K. J. (2019). Trends in hepatitis C treatment initiation among HIV/hepatitis C virus coinfected men engaged in primary care in a multisite community health centre in Maryland: A retrospective cohort study. BMJ Open, 9(3), e027411. https://doi.org/10.1136/bmjopen-2018-027411
   PubMed Web of Science ®Google Scholar
• Cheung, C. C., Ding, E., Sereda, P., Yip, B., Lourenco, L., Barrios, R., Montaner, J. S. G., Hogg, R. S., Lima, V., & Moore, D.M. (2016). Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001–2012. HIV Medicine, 17(9), 694–701. https://doi.org/10.1111/hiv.12379
   PubMed Web of Science ®Google Scholar
• Collins, L. F., Chan, A., Zheng, J., Chow, S.-C., Wilder, J. M., Muir, A. J., & Naggie, S. (2018). Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infectious Diseases, 5(1), ofx264. https://doi.org/10.1093/ofid/ofx264
   PubMed Web of Science ®Google Scholar
• Du, P., Jung, J., Kalidindi, Y., Farrow, K., Riley, T., & Whitener, C. (2020). Low utilization of direct-acting antiviral agents in a large national cohort of HIV and HCV coinfected medicare patients in the United States: Implications for HCV elimination. Journal of Public Health Management and Practice, https://doi.org/10.1097/PHH.0000000000001147. Online ahead of print.
   Google Scholar
• Flaer, P. J., Benjamin, P. L., Malow, R. M., Morisky, D. E., & Parkash, J. (2010). The growing cohort of seniors with HIV/AIDS: Changing the scope of Medicare Part D. AIDS Care, 22(7), 903–908. https://doi.org/10.1080/09540120903499188
   PubMed Web of Science ®Google Scholar
• Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clinical Infectious Diseases, 33(4), 562–569. https://doi.org/10.1086/321909
   PubMed Web of Science ®Google Scholar
• Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J-C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., & Telenti, A. (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study. The Lancet, 356(9244), 1800–1805. https://doi.org/10.1016/S0140-6736(00)03232-3
   PubMed Web of Science ®Google Scholar
• Hawkins, C., Grant, J., Ammerman, L. R., Palella, F., Mclaughlin, M., Green, R., Mcgregor, D., & Stosor, V. (2016). High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: A real-world perspective. Journal of Antimicrobial Chemotherapy, 71(9), 2642–2645. https://doi.org/10.1093/jac/dkw203
   PubMed Web of Science ®Google Scholar
• Hernando, V., Perez-Cachafeiro, S., Lewden, C., Gonzalez, J., Segura, F., Oteo, J. A., Rubio, R., Dalmau, D., Moreno, S., Amo, J. D. (2012). All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection. Journal of Hepatology, 57(4), 743–751. https://doi.org/10.1016/j.jhep.2012.06.010
   PubMed Web of Science ®Google Scholar
• Kalidindi, Y., Jung, J., Feldman, R., & Riley T. III. (2020). Association of direct-acting Antiviral Treatment with mortality Among Medicare beneficiaries with hepatitis C. JAMA Network Open, 3(7), e2011055. https://doi.org/10.1001/jamanetworkopen.2020.11055
   PubMed Web of Science ®Google Scholar
• Klein, M. B., Lalonde, R. G., & Suissa, S. (2003). The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 33(3), 365–372. https://doi.org/10.1097/00126334-200307010-00011
   PubMed Web of Science ®Google Scholar
• Kovari, H., Ledergerber, B., Cavassini, M., Ambrosioni, J., Bregenzer, A., Stöckle, M., Bernasconi, E., Kouyos, R., Weber, R., & Rauch, A. (2015). Swiss HIV Cohort Study. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 63(3), 573–580. https://doi.org/10.1016/j.jhep.2015.04.019
   PubMed Web of Science ®Google Scholar
• Kronfli, N., Bhatnagar, S. R., Hull, M. W., Moodie, E. M., Cox, J., Walmsley, S., Gill, J., Cooper, C., Martel-Laferrière, V., Pick, N., Klein, M. B., & Canadian Co-infection Cohort Investigators. (2019). Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. Aids (London, England), 33(6), 1013–1022. https://doi.org/10.1097/QAD.0000000000002156
   PubMedGoogle Scholar
• Lacombe, K., Fontaine, H., Dhiver, C., Metivier, S., Rosenthal, E., Antonini, T. Valantin, M. A., Miailhes, P., Harent, S., Batisse, D., Pageaux, G-P, Chas, J., Aumaitre, H., Dominguez, S., Allegre, T., Lafeuillade, A., Billaud, E., De Truchis, P., Perre, P., … Ceron, D. (2017). Real- world efficacy of da-clatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coin-fected patients with advanced liver disease in a French early access cohort. JAIDS Journal of Acquired Immune Deficiency Syndromes, 75(1), 97–107. https://doi.org/10.1097/QAI.0000000000001342
   PubMed Web of Science ®Google Scholar
• Marcus, J. L., Leyden, W. A., Chao, C. R., Xu, L., Quesenberry, C. P., Tien, P. C., Klein, D. B., Towner, W. J., Horberg, M. A., & Silverberg, M. J. (2015). Differences in response to antiretroviral therapy by Sex and hepatitis C infection status. AIDS Patient Care and STDs, 29(7), 370–378. https://doi.org/10.1089/apc.2015.0040
   PubMed Web of Science ®Google Scholar
• Oramasionwu, C. U., Moore, H. N., & Toliver, J. C. (2014). Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: A review. AIDS Patient Care and STDs, 28(5), 228–239. https://doi.org/10.1089/apc.2014.0033
   PubMed Web of Science ®Google Scholar
• Pham, T., Rathbun, R. C., Keast, S., Nesser, N., Farmer, K., & Skrepnek, G. (2019). National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. Journal of Evaluation in Clinical Practice, 25(5), 806–821. https://doi.org/10.1111/jep.13076
   PubMed Web of Science ®Google Scholar
• Rockstroh, J. K., Nelson, M., Katlama, C., Lalezari, J., Mallolas, J., Bloch, M., Matthews, G. V., Saag, M. S., Zamor, P. J., Orkin, C., Gress, J., Klopfer, S., Shaughnessy, M., Wahl, J., Nguyen, B-Y. T., Barr, E., Platt, H. L., Robertson, M. N., & Sulkowski, M. (2015). Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE COINFECTION): A non-randomised, open-label trial. The Lancet HIV, 2(8), e319–e327. https://doi.org/10.1016/S2352-3018(15)00114-9
   PubMed Web of Science ®Google Scholar
• Rockstroh, J. K., & Spengler, U. (2004). HIV and hepatitis C virus co-infection. The Lancet Infectious Diseases, 4(7), 437–444. https://doi.org/10.1016/S1473-3099(04)01059-X
   PubMed Web of Science ®Google Scholar
• Scott, J. A., & Chew, K. W. (2017). Treatment optimization for HIV/HCV co-infected patients. Therapeutic Advances in Infectious Disease, 4(1), 18–36. https://doi.org/10.1177/2049936116681279
   PubMed Web of Science ®Google Scholar
• Shrivastava, S., Bhatta, M., Ward, H., Romani, S., Lee, R., Lee, R., Rosenthal, E., Osinusi, A., Kohli, A., Masur, H., Kottilil, S., & Wilson, E. (2018). Multitarget direct-acting antiviral therapy is associated with superior immunologic recovery in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology Communications, 2(12), 1451–1466. https://doi.org/10.1002/hep4.1258
   PubMed Web of Science ®Google Scholar
• Sikavi, C., Chen, P. H., Lee, A. D., Saab, E. G., Choi, G., & Saab, S. (2018). Hepatitis C and human immunodeficiency virus coinfection in the era of directacting antiviral agents: No longer a difficult-to-treat population. Hepatology, 67(3), 847–857. https://doi.org/10.1002/hep.29642
   PubMed Web of Science ®Google Scholar
• Singal, A. G., Rich, N. E., Mehta, N., Branch, A. D., Pillai, A., Hoteit, M., Volk, M., Odewole, M., Scaglione, S., Guy, J., Said, A., Feld, J. J., John, B. V., Frenette, C., Mantry, P., Rangnekar, A. S., Oloruntoba, O., Leise, M., Jou J. H. … Murphy, C. C. (2019). Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology, 157(5), 1253–1263.e2. https://doi.org/10.1053/j.gastro.2019.07.040
   PubMed Web of Science ®Google Scholar
• Sogni, P., Gilbert, C., Lacombe, K., Piroth, L., Rosenthal, E., Miailhes, P., Gervais, A., Esterle, L., Chas, J., Poizot-Martin, I., Dominguez, S., Simon, A., Morlat, P., Neau, D., Zucman, D., Bouchaud, O., Lascoux-Combe, C., Bani-Sadr, F., Alric Laurent, … Wittkop, L. (2016). All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: Real-life results from the prospective ANRS CO13-HEPAVIH cohort. Clinical Infectious Diseases, 63(6), 763–770. https://doi.org/10.1093/cid/ciw379
   PubMed Web of Science ®Google Scholar
• U.S. Centers for Medicare & Medicaid Services. (2021a). CCW chronic condition algorithms. https://www2.ccwdata.org/documents/10280/19139421/ccw-chronic-condition-algorithms.pdf.
   Google Scholar
• U.S. Centers for Medicare & Medicaid Services. (2021b). CCW chronic condition algorithms- HIV/AIDS. https://www2.ccwdata.org/documents/10280/19140001/oth-cond-algo-hivaids.pdf.
   Google Scholar
• World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016–2021. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (2016)
   Google Scholar
• Wyles, D. L., Sulkowski, M. S., & Dieterich, D. (2016). Management of hepatitis C/HIV coinfection in the Era of highly Effective hepatitis C virus direct-acting antiviral therapy. Clinical Infectious Diseases, 63(Suppl 1), S3–S11. https://doi.org/10.1093/cid/ciw219
   PubMedGoogle Scholar
• Younossi, Z. M., Stepanova, M., Sulkowski, M., Naggie, S., Puoti, M., Orkin, C., & Hunt, S. L. (2015). Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: The impact on patient-reported outcomes. Journal of Infectious Diseases, 212(3), 367–377. https://doi.org/10.1093/infdis/jiv005
   PubMed Web of Science ®Google Scholar